×

Macrocure Ltd. to Present at Upcoming Nomura, Credit Suisse and Jefferies Health Care Conferences in November

PETACH TIKVA, Israel, Oct. 16, 2014 (GLOBE NEWSWIRE) -- Macrocure Ltd. (Nasdaq:MCUR), a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that Nissim Mashiach, Macrocure's President and Chief Executive Officer will present at multiple upcoming conferences in November. Additional members of the Management Team will also attend and be available for one-on-one meetings.

To view a live webcast of the Company's presentations, please visit Macrocure's Investor Relations website at http://investor.macrocure.com under 'Events & Presentations'.

Nomura Biotechnology Conference

  • Date: Thursday, November 6, 2014
  • Venue: Mandarin Oriental, Boston, Massachusetts

Credit Suisse 23rd Annual Healthcare Conference

  • Date: November 10 - 13, 2014
  • Presentation: Tuesday, November 11, 2014 at 3:30 PM PST; 6:30 PM EST
  • Venue: Arizona Biltmore, Phoenix, Arizona

Jefferies 2014 Global London Healthcare Conference

  • Date: November 19 - 20, 2014
  • Venue: The Waldorf Hilton, London, United Kingdom

About Macrocure Ltd.

Macrocure Ltd. is a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as DFUs and VLUs. The Company's novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body's own wound healing and regenerative components directly into the wound itself.

About CureXcell

Macrocure's lead product candidate, CureXcell, is a unique combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body's natural healing process. CureXcell is currently in two pivotal, Phase III, double-blind clinical trials targeting a broad indication for the treatment of all types of wounds below the knee. For more information, please visit: www.macrocure.com.

CONTACT: Francesca M. DeMartino Investor Relations & Corporate Communications Macrocure Ltd. (310) 739-6476; francesca@macrocure.com

Source:Macrocure